
|Articles|November 19, 2012
Sanofi lowers price of Zaltrap after Sloan-Kettering refusal to use it
Sanofi is lowering the price of ziv-aflibercept (Zaltrap) for previously treated colorectal cancer by half after physicians at Memorial Sloan Kettering Cancer Center (MSKCC) said that they would not use the drug, according to The New York Times.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Oral Semaglutide Show Promise as New Benchmark for Diabetes Care, Cardiovascular Protection
2
Limited Clinical Data Impact Cannabis Integration Into Standard Care | ASHP Midyear 2025
3
Opioid Overdose Deaths Fall by 34% in 2025 | ASHP Midyear 2025
4
Delgocitinib Improves Patients’ Chronic Hand Eczema
5




























































































































